keyword
https://read.qxmd.com/read/38626072/could-the-mitotic-count-improve-personalized-prognosis-in-melanoma-patients
#1
JOURNAL ARTICLE
Alessandra Buja, Massimo Rugge, Claudia Cozzolino, Francesca Dossi, Manuel Zorzi, Antonella Vecchiato, Giuseppe de Luca, Paolo Del Fiore, Saveria Tropea, Luigi dall'Olmo, Carlo Riccardo Rossi, Giovanna Boccuzzo, Simone Mocellin
A number of studies have indicated that the mitotic rate may be a predictive factor for poor prognosis in melanoma patients. The aim of this study was to investigate whether the mitotic rate is associated with other prognostic clinical and anatomopathological characteristics. After adjusting for other anatomopathological characteristics, we then verified the prognostic value of the number of mitoses, determining in which population subgroup this variable may have greater prognostic significance on 3-year mortality...
2024: PloS One
https://read.qxmd.com/read/38485189/pembrolizumab-versus-placebo-as-adjuvant-therapy-in-resected-stage-iib-or-iic-melanoma-outcomes-in-histopathologic-subgroups-from-the-randomized-double-blind-phase-3-keynote-716-trial
#2
JOURNAL ARTICLE
Dirk Schadendorf, Jason John Luke, Paolo A Ascierto, Georgina V Long, Piotr Rutkowski, Adnan Khattak, Michele Del Vecchio, Luis de la Cruz-Merino, Jacek Mackiewicz, Vanna Chiarion Sileni, John M Kirkwood, Caroline Robert, Jean-Jacques Grob, Reinhard Dummer, Matteo S Carlino, Yujie Zhao, Mizuho Kalabis, Clemens Krepler, Alexander Eggermont, Richard A Scolyer
BACKGROUND: Adjuvant pembrolizumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus placebo in the phase 3 KEYNOTE-716 study of resected stage IIB or IIC melanoma. At the prespecified third interim analysis (data cut-off, January 4, 2022), the HR for RFS in the overall population was 0.64 (95% CI, 0.50 to 0.84) and the HR for DMFS was 0.64 (95% CI, 0.47 to 0.88). We present a post hoc analysis of efficacy by subtypes defined by histopathologic characteristics...
March 13, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38436610/sentinel-lymph-node-biopsy-for-melanoma-in-the-older-population-a-prospective-analysis-of-outcomes
#3
JOURNAL ARTICLE
Murtaza Kadhum, Laura Mayr, Sophie Pope-Jones, Jonathan Cubitt, Sarah Hemington-Gorse
BACKGROUND: The use of sentinel lymph node biopsy (SLNB) in the older population, defined as those over 70 years old, has been debated since the adoption of SLNB into routine practice. Interestingly, there remains a paucity of evidence, especially regarding the rates of SLNB positivity, complications, and subsequent adjuvant therapy in those with node positivity. METHOD: Data on patient's comorbidities, positivity rates, complication rates, and subsequent adjuvant treatments were collected prospectively from 998 patients (644 patients < 70 and 354 patients ≥ 70 years old) between 2016 and 2022...
March 4, 2024: Journal of Surgical Oncology
https://read.qxmd.com/read/38339333/the-use-of-gene-expression-profiling-and-biomarkers-in-melanoma-diagnosis-and-predicting-recurrence-implications-for-surveillance-and-treatment
#4
REVIEW
James Sun, Kameko M Karasaki, Jeffrey M Farma
Cutaneous melanoma is becoming more prevalent in the United States and has the highest mortality among cutaneous malignancies. The majority of melanomas are diagnosed at an early stage and, as such, survival is generally favorable. However, there remains prognostic uncertainty among subsets of early- and intermediate-stage melanoma patients, some of whom go on to develop advanced disease while others remain disease-free. Melanoma gene expression profiling (GEP) has evolved with the notion to help bridge this gap and identify higher- or lower-risk patients to better tailor treatment and surveillance protocols...
January 30, 2024: Cancers
https://read.qxmd.com/read/38323030/the-effects-of-the-covid-19-pandemic-on-the-diagnosis-and-prognosis-of-melanoma-2%C3%A2-years-after-the-pandemic-in-two-romanian-counties
#5
JOURNAL ARTICLE
Adina Patricia Apostu, Ștefan Cristian Vesa, Simona Frățilă, Gabriela Iancu, Nona Bejinariu, Maximilian Muntean, Simona C Șenilă, Oana Alexandra Baba, Cristina Pop Secășan, Loredana Ungureanu
BACKGROUND: The COVID-19 pandemic disrupted the healthcare system and negatively affected the diagnosis and management of melanoma worldwide. The purpose of this study is to investigate the long-term effects of the COVID-19 pandemic on the diagnosis and prognosis of melanoma. MATERIALS AND METHODS: This retrospective cohort study included histopathologically confirmed melanoma cases from March 2019 to February 2023 in Cluj and Bihor counties. Data from the post-COVID-19 period (March 2021 to February 2023) were compared to the pre-COVID-19 period (March 2019 to February 2020) and the COVID-19 period (March 2020 to February 2021)...
2024: Frontiers in Medicine
https://read.qxmd.com/read/38278485/med15-atf1-rearranged-tumor-a-novel-cutaneous-tumor-with-melanocytic-differentiation
#6
JOURNAL ARTICLE
Jennifer S Ko, Julie Lemahieu, Steven D Billings, Franck Tirode, Diane Payton, Barbara Boone, Daniel Pissaloux, Arnaud de la Fouchardiere
We recently described novel dermal tumors with melanocytic differentiation and morphologic and biologic similarity to cutaneous clear cell sarcoma, including CRTC1::TRIM11 cutaneous tumor (CTCT), and clear cell tumors with melanocytic differentiation and either ACTIN::MITF (CCTMAM) or MITF::CREM (CCTMMC). Here we describe a series of three patients presenting with tumors reminiscent of CTCT, found to demonstrate a novel MED15::ATF1 fusion. All three patients were children (5-16 years old). Primary excision of Case 1 showed a circumscribed wedge-shaped silhouette with peripheral intercalation into collagen fibers and scattered lymphoid aggregates...
January 24, 2024: Modern Pathology
https://read.qxmd.com/read/38270618/efficacy-and-safety-of-guttiferone-e-in-melanoma-bearing-mice
#7
JOURNAL ARTICLE
Arthur Barcelos Ribeiro, Matheus Reis Santos de Melo, Marcela de Melo Junqueira, Mônica Garcia Leal Rodrigues, Thiago Olimpio de Souza, Gabriela Fernandes, Mário Ferreira Conceição Santos, Sérgio Ricardo Ambrósio, Jairo Kenupp Bastos, Denise Crispim Tavares
Melanoma, an aggressive and potentially fatal skin cancer, is constrained by immunosuppression, resistance, and high toxicity in its treatment. Consequently, there is an urgent need for innovative antineoplastic agents. Therefore, this study investigated the antimelanoma potential of guttiferone E (GE). In an allogeneic murine B16 melanoma model, GE was administered subcutaneously and intraperitoneally. Antitumor evaluation included tumor volume/weight measurements and histopathological and immunohistochemical analysis...
January 25, 2024: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38265469/pregnancy-associated-melanoma-characteristics-and-outcomes-from-2002-to-2020
#8
JOURNAL ARTICLE
Tara M Davidson, Tina J Hieken, Amy E Glasgow, Elizabeth B Habermann, Yiyi Yan
Melanoma diagnosed within 1 year of pregnancy is defined as pregnancy-associated melanoma (PAM). No robust data on how pregnancy influences melanoma nor guidelines for PAM management exist. With IRB approval, female patients with a pathology-confirmed melanoma diagnosis within 1 year of pregnancy treated at our institution from 2000 to 2020 were identified. Controls from the cancer registry were matched 1 : 4 when available on decade of age, year of surgery (±5), and stage. We identified 83 PAM patients with median follow-up of 86 months...
January 23, 2024: Melanoma Research
https://read.qxmd.com/read/38221928/incidence-of-braf-mutations-in-cutaneous-melanoma-histopathological-and-molecular-analysis-of-a%C3%A2-ukrainian-population
#9
JOURNAL ARTICLE
Oleksandr Dudin, Ozar Mintser, Nazarii Kobyliak, Dmytro Kaminskyi, Roman Shabalkov, Alina Matvieieva, Olga Sukhanova, Antonina Kalmykova, Denys Kozakov, Artem Mashukov, Oksana Sulaieva
AIM: This study aimed to investigate the incidence of BRAF mutation in cutaneous melanoma in the Ukrainian population with respect to clinical and histopathological data. MATERIALS & METHODS: This single-center retrospective cohort study enrolled 299 primary CM with known BRAF status assessed by RT-PCR. RESULTS: The overall BRAF mutation rate was 56.5% in CM and demonstrated a link with the younger age (p < 0.001), anatomical site (p < 0...
March 2023: Melanoma Management
https://read.qxmd.com/read/38216800/validation-of-the-melanoma-institute-of-australia-s-sentinel-lymph-node-biopsy-risk-prediction-tool-for-cutaneous-melanoma
#10
JOURNAL ARTICLE
Sainiteesh Maddineni, Matthew P Dizon, Vijaytha Muralidharan, Lexi A Young, John B Sunwoo, Fred M Baik, Susan M Swetter
BACKGROUND: For patients with cutaneous melanoma, sentinel lymph node biopsy (SLNB) is used to stage regional lymph nodes pathologically and inform prognosis, treatment, and surveillance. To reduce unnecessary surgeries, predictive tools aim to identify those at lowest risk for node-positive disease. The Melanoma Institute of Australia (MIA)'s Prediction Tool for Sentinel Node Metastasis Risk estimates risk of a positive SLNB using patient age and primary melanoma Breslow depth, histologic subtype, ulceration, mitotic rate, and lymphovascular invasion...
January 12, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38198163/population-based-validation-of-the-mia-and-mskcc-tools-for-predicting-sentinel-lymph-node-status
#11
JOURNAL ARTICLE
Roger Olofsson Bagge, Rasmus Mikiver, Michael A Marchetti, Serigne N Lo, Alexander C J van Akkooi, Daniel G Coit, Christian Ingvar, Karolin Isaksson, Richard A Scolyer, John F Thompson, Alexander H R Varey, Sandra L Wong, Johan Lyth, Edmund K Bartlett
IMPORTANCE: Patients with melanoma are selected for sentinel lymph node biopsy (SLNB) based on their risk of a positive SLN. To improve selection, the Memorial Sloan Kettering Cancer Center (MSKCC) and Melanoma Institute Australia (MIA) developed predictive models, but the utility of these models remains to be tested. OBJECTIVE: To determine the clinical utility of the MIA and MSKCC models. DESIGN, SETTING, AND PARTICIPANTS: This was a population-based comparative effectiveness research study including 10 089 consecutive patients with cutaneous melanoma undergoing SLNB from the Swedish Melanoma Registry from January 2007 to December 2021...
January 10, 2024: JAMA Surgery
https://read.qxmd.com/read/38158497/factors-affecting-recurrence-and-survival-for-patients-with-high-risk-stage-ii-melanoma
#12
JOURNAL ARTICLE
Aikaterini Dedeilia, Thinzar Lwin, Siming Li, Giuseppe Tarantino, Sasha Tunsiricharoengul, Aleigha Lawless, Tatyana Sharova, David Liu, Genevieve M Boland, Sonia Cohen
BACKGROUND: In the current era of effective adjuvant therapies and de-escalation of surgery, distinguishing which patients with high-risk stage II melanoma are at increased risk of recurrence after excision of the primary lesion is essential to determining appropriate treatment and surveillance plans. METHODS: A single-center retrospective study analyzed patients with stage IIB or IIC melanoma. Demographic and tumor data were collected, and genomic analysis of formalin-fixed, paraffin-embedded tissue samples was performed via an internal next-generation sequencing (NGS) platform (SNaPshot)...
December 29, 2023: Annals of Surgical Oncology
https://read.qxmd.com/read/38137712/scalp-melanoma-a-high-risk-subset-of-cutaneous-head-and-neck-melanomas-with-distinctive-clinicopathological-features
#13
JOURNAL ARTICLE
Rodolfo David Palacios-Diaz, Blanca de Unamuno-Bustos, Mónica Pozuelo-Ruiz, Enrico Giorgio Morales-Tedone, Rosa Ballester-Sánchez, Rafael Botella-Estrada
Scalp melanomas (SM) have been previously associated with poor overall and melanoma-specific survival rates. The aim of this study was to describe and compare the clinicopathological characteristics and survival outcomes of SM and non-scalp cutaneous head and neck melanoma (CHNM). An observational multi-center retrospective study was designed based on patients with CHNM followed in two tertiary care hospitals. A hundred and fifty-two patients had CHNM, of which 35 (23%) had SM. In comparison with non-scalp CHNM, SM were more frequently superficial spreading and nodular subtypes, had a thicker Breslow index median (2...
December 13, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38100196/can-angiotropism-and-lymphovascular-invasion-refine-the-current-cutaneous-melanoma-staging-system
#14
JOURNAL ARTICLE
Patricia Namubiru, William Dalleywater, Shaimaa Lashin, Somaia Elsheikh
BACKGROUND: Several prognostic factors for primary cutaneous melanoma (PCM) have been identified, and these predict metastasis and survival, to a certain extent. We sought to determine the frequency of angiotropism (AT) and lymphovascular invasion (LVI) in PCM and the relationship between AT, LVI, and other clinicopathological parameters and patient's prognosis. METHODS: This study included 538 cases of PCM diagnosed between 2003 and 2016. It comprised 246 females and 292 males whose clinicopathological variables were evaluated with respect to LVI and AT using univariate and multivariate analyses...
December 15, 2023: Journal of Cutaneous Pathology
https://read.qxmd.com/read/38059357/diagnostic-utility-of-the-23-gene-expression-profile-test-for-an-atypical-intradermal-melanocytic-proliferation
#15
JOURNAL ARTICLE
Etan Marks, Anais A Badia, Matthew S Goldberg
Ancillary tests such as immunohistochemistry (IHC) and gene expression profile (GEP) testing may be needed to arrive at a definitive diagnosis for some atypical melanocytic neoplasms. A 34-year-old male with a family history of melanoma presented with a large, heterogeneous melanocytic lesion on the cheek. Histopathological review of two biopsies revealed an atypical intradermal melanocytic proliferation with spitzoid features without ulceration or regression. Scattered mitotic figures were identified. In addition to performing SOX10 IHC, PRAME and HMB45 staining highlighted weak, patchy positivity that was stronger in superficial, pleomorphic melanocytes (Ki-67, 5-7% mitotic rate)...
December 7, 2023: Personalized Medicine
https://read.qxmd.com/read/38040339/histopathological-predictors-of-immune-related-adverse-events-among-patients-with-melanoma-treated-with-immune-checkpoint-inhibitors
#16
JOURNAL ARTICLE
Catherina X Pan, Mofei Liu, Charles B Lau, William C Lau, Daniel Y Kim, Shahin A Saberi, Rachael Rowley, Ruhi Kanwar, Anita Giobbie-Hurder, Nicole R LeBoeuf, Vinod E Nambudiri
No abstract text is available yet for this article.
November 29, 2023: Journal of the American Academy of Dermatology
https://read.qxmd.com/read/38013393/risk-factors-for-sentinel-lymph-node-metastasis-in-korean-acral-and-non-acral-melanoma-patients
#17
JOURNAL ARTICLE
Jee Yong Song, Young Jae Ryu, Ho Kyun Lee, Dong Hoon Lee, Yoo Duk Choi, Hyun Jeong Shim, Sook Jung Yun
Breslow thickness, ulceration, and mitotic rate are well-known prognostic factors for sentinel lymph node (SLN) metastasis in cutaneous melanoma. We investigated risk factors, including especially the degree of pigmentation, for SLN metastasis in Korean melanoma patients. We enrolled 158, composed of Korean 107 acral and 51 non-acral melanoma patients who underwent SLN biopsy. Clinicopathologic features such as Breslow thickness, ulceration, mitotic rate, and the degree of pigmentation were evaluated. The recurrence-free survival (RFS) rate and date of recurrence were determined...
November 27, 2023: Pigment Cell & Melanoma Research
https://read.qxmd.com/read/38003969/primary-melanoma-histopathologic-predictors-of-sentinel-lymph-node-positivity-a-proposed-scoring-system-for-risk-assessment-and-patient-selection-in-a-clinical-setting
#18
JOURNAL ARTICLE
Jelena Jeremić, Kristina Radenović, Milana Jurišić, Branko Suđecki, Milana Marinković, Jovan Mihaljević, Ivan Radosavljević, Milan Jovanović, Marina Stojanović, Nataša Milić, Vedrana Pavlović, Milan Stojičić, Zorka Inić, Marko Jović
Background and Objectives: The careful selection of adequate SLNB candidates not only aims at reducing the surgical risk while identifying SLN metastasis, but also plays a crucial role in identifying the patients eligible for adjuvant therapy. Objectives: The purpose of our study was to investigate the clinical and histologic aspects of primary melanomas that correlate with the likelihood of a positive SLNB result. Materials and Methods : A total of 101 primary melanoma patients who underwent sentinel lymph node biopsies were included in the study...
October 30, 2023: Medicina
https://read.qxmd.com/read/37910123/prognostic-significance-of-incipient-ulceration-in-primary-cutaneous-melanoma
#19
JOURNAL ARTICLE
Elizabeth C Paver, Tasnia Ahmed, Hazel Burke, Robyn P M Saw, Jonathan R Stretch, Andrew J Spillane, Kerwin F Shannon, Ismael A Vergara, David E Elder, Serigne N Lo, John F Thompson, Richard A Scolyer
IMPORTANCE: Ulceration represents a key feature in cutaneous melanoma, contributing to staging according to the current American Joint Committee on Cancer (AJCC) system. However, cases with incipient ulceration do not quite fulfill the AJCC definition of ulceration and are consequently classified as nonulcerated, presenting interpretive difficulty for pathologists. The prognostic implication of incipient ulceration is uncertain. OBJECTIVE: To evaluate the prognostic significance of incipient ulceration in cutaneous melanoma...
December 1, 2023: JAMA Dermatology
https://read.qxmd.com/read/37751620/acral-lentiginous-melanoma-a-clinicoprognostic-study-of-149-cases-at-a-single-institution
#20
JOURNAL ARTICLE
Xuejing Zheng, Wence Wu, Shengji Yu
OBJECTIVE: The objective of this study is to investigate the epidemiological features, clinical characteristics, and pathological characteristics of acral lentiginous melanoma (ALM) and identify prognostic factors. METHODS: A total of 149 patients diagnosed with ALM between August 2008 and December 2019 at the National Cancer Center (NCC) of China were retrospectively analyzed. Follow-up data on patient survival status were collected. Survival curves were generated using the Kaplan-Meier method, and statistical significance was assessed using the log-rank test...
September 26, 2023: American Surgeon
keyword
keyword
84991
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.